Categories: News

Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that President and CEO, Harry Simeonidis, and CFO, Spiro Sakiris, are scheduled to present at the LD Micro Invitational XIV Investor Conference to be held on April 8-9, 2024 in New York City.

LD Micro Invitational XIV Investment Conference
Dates: April 8-9, 2024
Location: Sofitel New York, NYC
Presentation: 12:00 p.m. ET on April 9, 2024
Webcast: https://ldinv14.sequireevents.com/

Management will be available during the event for 1×1 meetings with the investment community. To schedule a meeting please reach out to your LD Micro representative or KCSA Strategic Communications by emailing INBS@kcsa.com.

About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit: http://www.ibs.inc/

Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter

Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com

Staff

Recent Posts

Vent Creativity℠ Receives FDA-Clearance for AI-Powered Digital-Twin Knee Arthroplasty Planning Tool, Hermes.

Vent’s new web-based software is now available for clinical use in the US, starting with…

6 hours ago

Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years

Investment builds on almost 140-year legacy of improving and saving lives and supporting American jobs…

6 hours ago

Genmab, NHS England, Pistoia Alliance and Regeneron Win Bio-IT World Innovative Practices Awards

Organizations to be Featured During Friday Sessions ofBio-IT World Conference & Expo, April 2-4 in…

6 hours ago

US Healthcare Analytics Market worth US$47.40 billion by 2029 with 24.5% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., March 21, 2025 /PRNewswire/ -- The global US Healthcare Analytics Market, valued at…

12 hours ago

Task Trainers Market to Reach $2.9 Billion by 2032–Exclusive Report by Meticulous Research®

REDDING, Calif., March 21, 2025 /PRNewswire/ -- According to a new market research report titled 'Task…

12 hours ago